Catalog No.
PMD80801
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse CD38/ADPRC 1 (Lys60-Thr304).
Applications
ELISA, IHC, WB
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000 |
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Purification
Purified by antigen affinity column.
Accession
P56528
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note
For research use only.
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects., PMID:40013150
Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study., PMID:40037111
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review., PMID:40052837
CD31 + naïve T cells associate with immunosenescence and responsiveness to multiple vaccines in older adults., PMID:40055790
CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention., PMID:40057636
Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1-infected CD4+ T cells by ADCC., PMID:40073240
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma., PMID:40073374
Evolution of Survival in Patients with Multiple Myeloma over Two Decades: A Real-World Experience from a Medium-Level Hospital., PMID:40075641
How First-Line Therapy is Changing in Transplant-Eligible Multiple Myeloma Patients., PMID:40084095
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences., PMID:40084104
How First-Line Therapy is Changing in non-Transplant Eligible Multiple Myeloma Patients., PMID:40084107
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury., PMID:40085948
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020., PMID:40087879
T-cell activation and senescence in asymptomatic HIV/Leishmania infantum co-infection., PMID:40096173
The effects of intragraft CD38+ B cell on chronic active antibody mediated rejection in kidney transplantation., PMID:40111715
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis., PMID:40122729
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab., PMID:40124649
Impact of Protein Kinase C Activation and Monoclonal Antibodies on Immune Checkpoint Regulation and B Cell Function in Patients with Chronic Lymphocytic Leukemia., PMID:40149717
Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis., PMID:40176408
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data., PMID:40199119
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse., PMID:40241199
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells., PMID:40245922
Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer's disease., PMID:40254603
Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression., PMID:40259818
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group., PMID:40271095
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q., PMID:40282438
Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoring., PMID:40288549
Kinetics of the humoral and cellular immune response up to 1 year from mpox virus infection., PMID:40294869
Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies., PMID:40301559
CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity., PMID:40315226
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma., PMID:40335949
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM., PMID:40343678
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Daratumumab monotherapy as a desensitization strategy prior to cardiac transplantation., PMID:40407767
Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months., PMID:40416973
Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen., PMID:40422527
Targeting CD38 in Antibody-Mediated Rejection., PMID:40444214
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma., PMID:40447948
A ROS-Responsive Dual-Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T-Cell Acute Lymphoblastic Leukemia., PMID:40448620
Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma., PMID:40453054
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class Exposed, Relapsed or Refractory Multiple Myeloma., PMID:40465403
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis., PMID:40473556
Antibody-mediated ratiometric delivery of FLT3 and CDK4/6 dual inhibitors for targeted treatment of acute myeloid leukemia., PMID:40482924
Daratumumab for Treatment of Acute Antibody-Mediated Rejection in a Pediatric Kidney Transplant Recipient., PMID:40490910
Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials., PMID:40501427
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study., PMID:40518372
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series., PMID:40528367
For research use only. Not for human or drug use.
